| Literature DB >> 750188 |
F Z Stanczyk, P F Brenner, D R Mishell, A Ortiz, E K Gentzschein, U Goebelsmann.
Abstract
A sensitive and reliable radioimmunoassay (RIA) for the measurement of norethindrone (NET) in serum has been established employing anti-11 alpha-hydroxynorethindrone 11-hemisuccinyl-bovine serum albumin serum in conjunction with norethindrone-3-(0-carboxymethyl) oximino-[125I]-iodohistamine. Of a number of ring A reduced NET metabolites, only 17 beta-hydroxy-17 alpha-ethinyl-5 beta-estran-3-one (43%) and 17 alpha-ethinyl-5 alpha-estrane-3 beta, 17 beta-diol (15.7%) cross-reacted appreciably in this RIA. Ethinyl estradiol (EE2) and mestranol (MEE2) exhibited cross-reactions of only 1.1 and 0.4%, respectively. Serum NET levels were measured in four groups of 3 women, each ingesting either 1 mg NET plus 0.05 mg MEE2 (Norinyl 1 + 50 or Ortho Novum 1/50), 0.5 mg NET plus 0.035 mg EE2 (Brevicon) or only 0.35 mg NET (Micronor) daily for 5 consecutive days. Peak serum NET levels were observed within 1/2 to 4 hours after oral intake and fell precipitously thereafter. After reaching a maximum, serum NET concentrations declined in a manner consistent with at least two disposition phases. The average half-life for the first disposition phase was 2.3, 3.4, 3.9 and 4.4 hours in subjects ingesting Norinyl 1 + 50, Ortho Novum 1/50, Brevicon and Micronor, respectively. Peak and 3-hour post-ingestion serum NET concentrations were dose-related but showed considerable subject-to-subject variations. Following discontinuation of tablet intake, serum NET levels remained detectable (greater than 0.05 ng/ml) for at least 5 days in all 3 women who had taken Ortho Novum 1/50, but in none of the other 9 volunteers. These results suggest that different preparations of identical doses and combinations of oral contraceptive steroids may yield different serum NET profiles. However, due to considerable subject-to-subject variations, larger numbers of subjects are required for a conclusive investigation.Entities:
Keywords: Clinical Research; Contraception; Contraceptive Agents, Estrogen--side effects; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents, Progestin--analysis; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--administraction and dosage; Contraceptive Agents--analysis; Contraceptive Agents--side effects; Ethinyl Estradiol; Examinations And Diagnoses; Family Planning; Laboratory Examinations And Diagnoses; Laboratory Procedures; Mestranol--side effects; Norethindrone--administraction and dosage; Norethindrone--analysis; Norethindrone--side effects; Norethynodrel--side effects; Oral Contraceptives; Oral Contraceptives, Combined; Progestins, Low-dose--side effects; Research Methodology
Mesh:
Substances:
Year: 1978 PMID: 750188 DOI: 10.1016/0010-7824(78)90046-x
Source DB: PubMed Journal: Contraception ISSN: 0010-7824 Impact factor: 3.375